Sign in to edit your profile (add interests, mentoring, photo, etc.)

    William Stohl, MD, PhD

    TitleProfessor
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressHMR 711
    Health Sciences Campus
    Los Angeles California 90089-9099
    Phone+1 323 442 1959

       Biography 
       Awards and Honors
      American College of Physicians2012Fellow (FACP)

       Overview 
       Overview
      Dr. Stohl’s research focus is on systemic lupus erythematosus (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); rheumatoid arthritis (pathogenesis, natural course of disease, treatment, animal models, immunologic disturbances, novel therapeutics); and B cells (basic biology, role in autoimmune diseases, development of targeted therapies).

      Dr. Stohl received his Ph.D. (1979) and his M.D. (1977) from the University Pennsylvania.


       ORNG Applications 
       Featured Videos
       In The News

       Bibliographic 
       Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Hamm-Alvarez SF, Janga SR, Edman MC, Madrigal S, Shah M, Frousiakis SE, Renduchintala K, Zhu J, Bricel S, Silka K, Bach D, Heur M, Christianakis S, Arkfeld DG, Irvine J, Mack WJ, Stohl W. Tear Cathepsin S as a Candidate Biomarker for Sjögren's Syndrome. Arthritis Rheumatol. 2014 Jul; 66(7):1872-81.
        View in: PubMed
      2. Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, Chen H, Lee SH, Leung I, Bonzon C, Desjarlais JR, Stohl W, Szymkowski DE. Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fc? Receptor IIb Inhibitory Receptor. Arthritis Rheumatol. 2014 May; 66(5):1153-64.
        View in: PubMed
      3. Stohl W. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus. Expert Opin Ther Targets. 2014 Apr; 18(4):473-89.
        View in: PubMed
      4. Sindhava VJ, Scholz JL, Stohl W, Cancro MP. APRIL mediates peritoneal B-1 cell homeostasis. Immunol Lett. 2014 Aug; 160(2):120-7.
        View in: PubMed
      5. Goenka R, Matthews AH, Zhang B, O'Neill PJ, Scholz JL, Migone TS, Leonard WJ, Stohl W, Hershberg U, Cancro MP. Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation. J Exp Med. 2014 Jan 13; 211(1):45-56.
        View in: PubMed
      6. Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
        View in: PubMed
      7. Stohl W. Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2013 Dec; 9(12):705-20.
        View in: PubMed
      8. Shah HB, Joshi SK, Rampuria P, Devera TS, Lang GA, Stohl W, Lang ML. BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand. J Immunol. 2013 Aug 1; 191(3):1154-63.
        View in: PubMed
      9. Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89.
        View in: PubMed
      10. Jacob CO, Yu N, Guo S, Jacob N, Quinn WJ, Sindhava V, Cancro MP, Goilav B, Putterman C, Migone TS, Stohl W. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum. 2013 Apr; 65(4):1043-54.
        View in: PubMed
      11. Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2013 Feb; 65(2):299-303.
        View in: PubMed
      12. Stohl W. Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development? Curr Rheumatol Rep. 2012 Aug; 14(4):303-9.
        View in: PubMed
      13. Kong N, Lan Q, Chen M, Zheng T, Su W, Wang J, Yang Z, Park R, Dagliyan G, Conti PS, Brand D, Liu Z, Zou H, Stohl W, Zheng SG. Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells. Ann Rheum Dis. 2012 Sep; 71(9):1567-72.
        View in: PubMed
      14. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul; 64(7):2328-37.
        View in: PubMed
      15. Kawatkar AA, Hay JW, Stohl W, Nichol MB. Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ. 2013 Jul; 22(7):807-23.
        View in: PubMed
      16. Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol. 2012 Aug; 39(8):1632-40.
        View in: PubMed
      17. Jacob CO, Guo S, Jacob N, Pawar RD, Putterman C, Quinn WJ, Cancro MP, Migone TS, Stohl W. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum. 2012 May; 64(5):1610-9.
        View in: PubMed
      18. Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA, Ashrafzadeh A, Grzeschik S, Bieraugel R, Green J, Francom S, Dummer W. Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis. 2012 Aug; 71(8):1289-96.
        View in: PubMed
      19. Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol. 2012; 30(1):69-77.
        View in: PubMed
      20. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
        View in: PubMed
      21. Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012 Mar; 71(3):351-7.
        View in: PubMed
      22. Zhou X, Xia Z, Lan Q, Wang J, Su W, Han YP, Fan H, Liu Z, Stohl W, Zheng SG. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One. 2011; 6(8):e23629.
        View in: PubMed
      23. Jacob N, Stohl W. Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther. 2011; 13(4):228.
        View in: PubMed
      24. Stohl W, Scholz JL, Cancro MP. Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol. 2011 May; 23(3):305-10.
        View in: PubMed
      25. Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, Jacob CO, Stohl W. B Cell and BAFF dependence of IFN-a-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol. 2011 Apr 15; 186(8):4984-93.
        View in: PubMed
      26. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE. Antibody-mediated coengagement of Fc?RIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol. 2011 Apr 1; 186(7):4223-33.
        View in: PubMed
      27. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011 Jan; 70(1):39-46.
        View in: PubMed
      28. Stohl W, Jacob N, Guo S, Morel L. Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum. 2010 Aug; 62(8):2432-42.
        View in: PubMed
      29. Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2010; 12(2):111.
        View in: PubMed
      30. Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity. 2010 Feb; 43(1):84-97.
        View in: PubMed
      31. Mavragani CP, La DT, Stohl W, Crow MK. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. Arthritis Rheum. 2010 Feb; 62(2):392-401.
        View in: PubMed
      32. Hong SD, Reiff A, Yang HT, Migone TS, Ward CD, Marzan K, Shaham B, Phei WC, Garza J, Bernstein B, Stohl W. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009 Nov; 60(11):3400-9.
        View in: PubMed
      33. Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Koss MN, Stohl W, Kovats S, Jacob CO. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol. 2009 Nov 1; 183(9):6021-9.
        View in: PubMed
      34. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther. 2009; 11(5):R143.
        View in: PubMed
      35. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
        View in: PubMed
      36. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
        View in: PubMed
      37. Jacob N, Yang H, Pricop L, Liu Y, Gao X, Zheng SG, Wang J, Gao HX, Putterman C, Koss MN, Stohl W, Jacob CO. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol. 2009 Feb 15; 182(4):2532-41.
        View in: PubMed
      38. Collins CE, La DT, Yang HT, Massin F, Gibot S, Faure G, Stohl W. Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2009 Nov; 68(11):1768-74.
        View in: PubMed
      39. Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
        View in: PubMed
      40. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008 Aug; 58(8):2453-9.
        View in: PubMed
      41. Stohl W, Jacob N, Quinn WJ, Cancro MP, Gao H, Putterman C, Gao X, Pricop L, Koss MN. Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol. 2008 Jul 1; 181(1):833-41.
        View in: PubMed
      42. La DT, Collins CE, Yang HT, Migone TS, Stohl W. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders. Ann Rheum Dis. 2008 Aug; 67(8):1132-8.
        View in: PubMed
      43. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis. 2008 Jul; 67(7):1011-6.
        View in: PubMed
      44. Looney RJ, Stohl W. New and promising treatments for rheumatoid arthritis. Am J Orthop (Belle Mead NJ). 2007 Jul; 36(7 Suppl):18-23.
        View in: PubMed
      45. Stohl W. Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases. Endocr Metab Immune Disord Drug Targets. 2006 Dec; 6(4):351-8.
        View in: PubMed
      46. Schaller M, Stohl W, Benoit V, Tan SM, Johansen L, Ditzel HJ. Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI). Biochem Biophys Res Commun. 2006 Oct 20; 349(2):838-45.
        View in: PubMed
      47. Jacob CO, Pricop L, Putterman C, Koss MN, Liu Y, Kollaros M, Bixler SA, Ambrose CM, Scott ML, Stohl W. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006 Aug 15; 177(4):2671-80.
        View in: PubMed
      48. Stohl W, Looney RJ. B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks? Clin Immunol. 2006 Oct; 121(1):1-12.
        View in: PubMed
      49. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA. TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol. 2006 Mar 15; 176(6):3321-9.
        View in: PubMed
      50. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006 Mar; 54(3):723-32.
        View in: PubMed
      51. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006; 8(1):R6.
        View in: PubMed
      52. Stohl W, Xu D, Kim KS, Tedder TF, Sato S. Humoral autoimmunity in mice overexpressing B cell surface CD19: vital role for MHC class II. Clin Immunol. 2005 Sep; 116(3):257-64.
        View in: PubMed
      53. Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B, Metzger TE, Bixler SA, Hong YS, Ambrose CM, Mackay F, Morel L, Putterman C, Kotzin BL, Kalled SL. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 2005 Jul; 52(7):2080-91.
        View in: PubMed
      54. Stohl W. BlySfulness does not equal blissfulness in systemic lupus erythematosus: a therapeutic role for BLyS antagonists. Curr Dir Autoimmun. 2005; 8:289-304.
        View in: PubMed
      55. Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, Gilmore W, Cheema GS, Stohl W, Burnett ME, Ko D, Kachuck NJ, Weiner LP. Increased CXCL8 (IL-8) expression in Multiple Sclerosis. J Neuroimmunol. 2004 Oct; 155(1-2):161-71.
        View in: PubMed
      56. Schaller M, Stohl W, Tan SM, Benoit VM, Hilbert DM, Ditzel HJ. Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis. Ann Rheum Dis. 2005 May; 64(5):743-9.
        View in: PubMed
      57. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Roschke V, Wu Y, Baker KP, Hilbert DM. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis. 2004 Sep; 63(9):1096-103.
        View in: PubMed
      58. Stohl W, Xu D, Metzger TE, Kim KS, Morel L, Kotzin BL. Dichotomous effects of complete versus partial class II major histocompatibility complex deficiency on circulating autoantibody levels in autoimmune-prone mice. Arthritis Rheum. 2004 Jul; 50(7):2227-39.
        View in: PubMed
      59. Stohl W. Targeting B lymphocyte stimulator in systemic lupus erythematosus and other autoimmune rheumatic disorders. Expert Opin Ther Targets. 2004 Jun; 8(3):177-89.
        View in: PubMed
      60. Stohl W, Xu D, Kim KS, David CS, Allison JP. MHC class II-independent and -dependent T cell expansion and B cell hyperactivity in vivo in mice deficient in CD152 (CTLA-4). Int Immunol. 2004 Jul; 16(7):895-904.
        View in: PubMed
      61. Stohl W. A therapeutic role for BLyS antagonists. Lupus. 2004; 13(5):317-22.
        View in: PubMed
      62. Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003 Dec; 48(12):3475-86.
        View in: PubMed
      63. Kim KS, Jacob N, Stohl W. In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens. Clin Immunol. 2003 Sep; 108(3):182-9.
        View in: PubMed
      64. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum. 2003 Apr; 48(4):982-92.
        View in: PubMed
      65. Stohl W. SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther. 2003; 5(3):136-8.
        View in: PubMed
      66. Roschke V, Sosnovtseva S, Ward CD, Hong JS, Smith R, Albert V, Stohl W, Baker KP, Ullrich S, Nardelli B, Hilbert DM, Migone TS. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol. 2002 Oct 15; 169(8):4314-21.
        View in: PubMed
      67. Stohl W. Systemic lupus erythematosus: a blissless disease of too much BLyS (B lymphocyte stimulator) protein. Curr Opin Rheumatol. 2002 Sep; 14(5):522-8.
        View in: PubMed
      68. Stohl W, Cheema GS, Briggs WS, Xu D, Sosnovtseva S, Roschke V, Ferrara DE, Labat K, Sattler FR, Pierangeli SS, Hilbert DM. B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients. Clin Immunol. 2002 Aug; 104(2):115-22.
        View in: PubMed
      69. Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep. 2002 Aug; 4(4):345-50.
        View in: PubMed
      70. Stohl W, Xu D, Zang S, Kim KS, Li L, Hanson JA, Stohlman SA, David CS, Jacob CO. In vivo staphylococcal superantigen-driven polyclonal Ig responses in mice: dependence upon CD4(+) cells and human MHC class II. Int Immunol. 2001 Oct; 13(10):1291-300.
        View in: PubMed
      71. Parr TB, Hofman FM, Kiener PA, Stohl W. Cell cycle phase-specific survival of CD95 ligand-challenged Jurkat cells: upregulation of heat-shock response. Cell Immunol. 2001 Jul 10; 211(1):21-9.
        View in: PubMed
      72. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001 Jun; 44(6):1313-9.
        View in: PubMed
      73. Stohl W, Xu D, Starling GC, Casali P, Kiener PA. Promotion of activated human B cell apoptosis and inhibition of Ig production by soluble CD95 ligand: CD95-based downregulation of Ig production need not culminate in activated B cell death. Cell Immunol. 2000 Jul 10; 203(1):1-11.
        View in: PubMed
      74. Stohl W, Hamilton AS, Deapen DM, Mack TM, Horwitz DA. Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells. Lupus. 1999; 8(4):293-9.
        View in: PubMed
      75. Stohl W, Lynch DH, Starling GC, Kiener PA. Superantigen-driven, CD8+ T cell-mediated down-regulation: CD95 (Fas)-dependent down-regulation of human Ig responses despite CD95-independent killing of activated B cells. J Immunol. 1998 Oct 1; 161(7):3292-8.
        View in: PubMed
      76. Stohl W, Elliott JE, Lynch DH, Kiener PA. CD95 (Fas)-based, superantigen-dependent, CD4+ T cell-mediated down-regulation of human in vitro immunoglobulin responses. J Immunol. 1998 Jun 1; 160(11):5231-8.
        View in: PubMed
      77. Sumida T, Maeda T, Taniguchi M, Nishioka K, Stohl W. TCR AV24 gene expression in double negative T cells in systemic lupus erythematosus. Lupus. 1998; 7(8):565-8.
        View in: PubMed
      78. Stohl W, Elliott JE, Li L, Podack ER, Lynch DH, Jacob CO. Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin. Arthritis Rheum. 1997 Jun; 40(6):1130-7.
        View in: PubMed
      79. Stohl W, Elliott JE, Hamilton AS, Deapen DM, Mack TM, Horwitz DA. Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation. Studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum. 1996 Nov; 39(11):1840-51.
        View in: PubMed
      80. Stohl W, Arkfeld DG. Treatment of rheumatoid arthritis. N Engl J Med. 1996 Sep 12; 335(11):821-2; author reply 822-3.
        View in: PubMed
      81. Stohl W, Elliot JE. In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol. 1996 May; 79(2):122-33.
        View in: PubMed
      82. Stohl W, Elliott JE. Differential human T cell-dependent B cell differentiation induced by staphylococcal superantigens (SAg). Regulatory role for SAg-dependent B cell cytolysis. J Immunol. 1995 Aug 15; 155(4):1838-50.
        View in: PubMed
      83. Stohl W. Impaired polyclonal T cell cytolytic activity. A possible risk factor for systemic lupus erythematosus. Arthritis Rheum. 1995 Apr; 38(4):506-16.
        View in: PubMed
      84. Stohl W, Elliott JE, Wang H, Lin YG, Horwitz DA. Enhancing effects of interleukin 2-treated peripheral blood mononuclear cells on subsequent B cell differentiation. Cell Immunol. 1994 Sep; 157(2):381-92.
        View in: PubMed
      85. Stohl W, Elliott JE, Linsley PS. Human T cell-dependent B cell differentiation induced by staphylococcal superantigens. J Immunol. 1994 Jul 1; 153(1):117-27.
        View in: PubMed
      86. Stohl W, Elliott JE, Linsley PS. Polyclonal in vitro T cell proliferation and T cell-dependent B cell differentiation supported by activated autologous B cells. Clin Immunol Immunopathol. 1994 Jul; 72(1):44-52.
        View in: PubMed
      87. Stohl W, Elliott JE. Stimulation of human peripheral blood mononuclear cells with anti-CD3 monoclonal antibody vs IL2: disparate effects on T cell-dependent B cell differentiation despite similar effects on generation of unrestricted cytolytic activity. Clin Immunol Immunopathol. 1992 Oct; 65(1):30-8.
        View in: PubMed
      88. Stohl W. Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus. Clin Immunol Immunopathol. 1992 May; 63(2):163-72.
        View in: PubMed
      89. Spertini F, Stohl W, Ramesh N, Moody C, Geha RS. Induction of human T cell proliferation by a monoclonal antibody to CD5. J Immunol. 1991 Jan 1; 146(1):47-52.
        View in: PubMed
      90. Stohl W, Crow MK. Inhibition by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell-dependent B cell activation. Cell Immunol. 1990 Oct 15; 130(2):257-70.
        View in: PubMed
      91. Stohl W, Hofman FM, Gray JD. Differential CD3/T cell antigen receptor-mediated IL-2 production in jurkat T cells. Dissociation of IL-2 response from total inositol phosphate and calcium responses. J Immunol. 1990 Aug 15; 145(4):1078-87.
        View in: PubMed
      92. Stohl W, Tovar Z, Talal N. Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and -dependent components. J Immunol. 1990 May 15; 144(10):3718-25.
        View in: PubMed
      93. Shiba K, Stohl W, Gray JD, Horwitz DA. A novel role for accessory cells in T cell-dependent B cell differentiation. Cell Immunol. 1990 May; 127(2):458-69.
        View in: PubMed
      94. Stohl W, Gottlieb AB, Reeves WH. A functionally unique anti-CD3 monoclonal antibody cross-reactive with basal keratinocytes. Cell Immunol. 1989 Jul; 121(2):247-60.
        View in: PubMed
      95. Crow MK, Kushner B, Jover JA, Friedman SM, Mechanic SE, Stohl W. Human peripheral blood T helper cell-induced B cell activation results in B cell surface expression of the CD23 (BLAST-2) antigen. Cell Immunol. 1989 Jun; 121(1):99-112.
        View in: PubMed
      96. Stohl W, Linker-Israeli M. Inhibitory effects of anti-CD2 monoclonal antibodies on interleukin 2 production and interleukin 2 receptor expression in anti-CD3-induced T cell activation. Cell Immunol. 1989 May; 120(2):351-65.
        View in: PubMed
      97. Sherris D, Stohl W, Mayer L. Characterization of lymphokines mediating B cell growth and differentiation from monoclonal anti-CD3 antibody-stimulated T cells. J Immunol. 1989 Apr 1; 142(7):2343-51.
        View in: PubMed
      98. Mayer L, Stohl W, Cunningham-Rundles C. Feedback inhibition of B cell differentiation by monomeric immunoglobulin. Int Rev Immunol. 1989; 5(2):189-95.
        View in: PubMed
      99. Stohl W, Cunningham-Rundles C, Mayer L. In vitro induction of T cell-dependent B cell differentiation in patients with common varied immunodeficiency. Clin Immunol Immunopathol. 1988 Nov; 49(2):273-82.
        View in: PubMed
      100. Stohl W, Posnett DN, Chiorazzi N. Differential immunomodulation by anti-CD2 monoclonal antibodies of anti-CD3-induced T cell activation: dependence upon the individual anti-CD3 monoclonal antibody used for activation. Cell Immunol. 1988 Oct 1; 116(1):73-85.
        View in: PubMed
      101. Stohl W, Singer JZ. Correlation between systemic lupus erythematosus and T4 epitope phenotype. Arthritis Rheum. 1987 Dec; 30(12):1412-5.
        View in: PubMed
      102. Stohl W, Mayer L. Inhibition of T cell-dependent human B cell proliferation and B cell differentiation by polyspecific monomeric IgG. Clin Exp Immunol. 1987 Dec; 70(3):649-57.
        View in: PubMed
      103. Stohl W, Posnett DN, Chiorazzi N. Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies. J Immunol. 1987 Mar 15; 138(6):1667-73.
        View in: PubMed
      104. Stohl W, Cunningham-Rundles C, Thompson C, Mayer L. Modulation of the immune response by immunoglobulin for intravenous use. II. Inhibitory effects of sera from treated patients. Clin Immunol Immunopathol. 1986 Nov; 41(2):273-80.
        View in: PubMed
      105. Stohl W. Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol. 1986 Jun 15; 136(12):4407-13.
        View in: PubMed
      106. Stohl W. Modulation of the immune response by immunoglobulin for intravenous use. I. Inhibition of pokeweed mitogen-induced B cell differentiation. Clin Exp Immunol. 1985 Oct; 62(1):200-7.
        View in: PubMed
      107. Stohl W, Crow MK, Kunkel HG. Systemic lupus erythematosus with deficiency of the T4 epitope on T helper/inducer cells. N Engl J Med. 1985 Jun 27; 312(26):1671-8.
        View in: PubMed
      108. Stohl W, Kunkel HG. Heterogeneity in expression of the T4 epitope in black individuals. Scand J Immunol. 1984 Sep; 20(3):273-8.
        View in: PubMed
      109. Stohl W. Deficient OKT4 epitope on helper T cells in patient with SLE: confusion with AIDS. N Engl J Med. 1984 Jun 7; 310(23):1531.
        View in: PubMed
      110. Stohl W, Gonatas NK. Detection of the precursor and effector cells of experimental allergic encephalomyelitis in the thoracic duct of the rat. Cell Immunol. 1980 Sep 1; 54(2):471-7.
        View in: PubMed
      111. Stohl W. Saturday classes and rounds. N Engl J Med. 1979 May 17; 300(20):1165.
        View in: PubMed
      112. Stohl W, Kaplan MS, Gonatas NK. A quantitative assay for experimental allergic encephalomyelitis in the rat based on permeability of spinal cords to 125I-human gamma-globulin. J Immunol. 1979 Mar; 122(3):920-5.
        View in: PubMed
      113. Stohl W, Gonatas NK. Chronic permeability of the central nervous system to mononuclear cells in experimental allergic encephalomyelitis in the Lewis rat. J Immunol. 1978 Sep; 121(3):844-50.
        View in: PubMed
      114. Stohl W. Religious objections to autopsy. N Engl J Med. 1977 Oct 27; 297(17):953.
        View in: PubMed
      115. Stohl W, Gonatas NK. Distribution of the thy-1 antigen in cellular and subcellular fractions of adult mouse brain. J Immunol. 1977 Aug; 119(2):422-7.
        View in: PubMed
      Back to TOP